Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease

References

• Marjama-Lyons JM, Koller WC. Parkinson’s disease. Update in diagnosis and symptom management. Geriatrics 56(8), 24–35 (2001).
   PubMed Web of Science ®Google Scholar
• Schulz JB, Falkenburger BH. Neuronal pathology in Parkinson’s disease. Cell Tissue Res. 318(1), 135–147 (2004).
   PubMed Web of Science ®Google Scholar
• Guttman M, Kish SJ, Furukawa Y. Current concepts in the diagnosis and management of Parkinson’s disease. Can. Med. Assoc. J. 168(3), 293–301 (2003).
   PubMed Web of Science ®Google Scholar
• Hamani C, Lozano AM. Physiology and pathophysiology of Parkinson’s disease. Ann. NY Acad. Sci. 991, 15–21 (2003).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Agid Y, Mizuno Y et al. Levodopa in the treatment of Parkinson’s disease: current controversies. Mov. Disord. 19(9), 997–1005 (2004).
   PubMed Web of Science ®Google Scholar
• Fahn S. Developments in Parkinson’s disease therapy. N. Am. Pharmacother. 2, 186–187 (2004).
   Google Scholar
• Jankovic J. Levodopa strengths and weaknesses. Neurology 58(4 Suppl. 1), S19–S32 (2002).
   Google Scholar
• Hardie RJ, Lees AJ, Stern GM. On–off fluctuations in Parkinson’s disease. A clinical and neuropharmacological study. Brain 107, 487–506 (1984).
   PubMed Web of Science ®Google Scholar
• Sage JI, Mark MH. Drenching sweats as an off phenomenon in Parkinson’s disease: treatment and relation to plasma levodopa profile. Ann. Neurol. 37(1), 120–122 (1995).
   PubMed Web of Science ®Google Scholar
• Obeso JA, Grandas F, Vaamonde J et al. Motor complications associated with chronic levodopa therapy in Parkinson’s disease. Neurology 39(11 Suppl. 2), 11–19 (1989).
   PubMed Web of Science ®Google Scholar
• Reardon KA, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson’s disease: a longitudinal study over 6 years. Mov. Disord. 14(4), 605–611 (1999).
   PubMed Web of Science ®Google Scholar
• Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson’s disease on the quality of life. Mov. Disord. 20(2), 224–230 (2005).
   PubMed Web of Science ®Google Scholar
• Maurel F, Lilliu H, Le Pen C. Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson’s disease. Rev. Neurol. (Paris) 157(5), 507–514 (2001).
   PubMed Web of Science ®Google Scholar
• Clarke CE. Medical management of Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 72(Suppl. 1), 22–27 (2002).
   PubMed Web of Science ®Google Scholar
• Dewey RB Jr. Management of motor complications in Parkinson’s disease. Neurology 62(6 Suppl. 4), S3–S7 (2004).
   Google Scholar
• Samii A, Nutt JG, Ransom BR. Parkinson’s disease. Lancet 363(9423), 1783–1793 (2004).
   PubMed Web of Science ®Google Scholar
• Lang AE, Lozano AM. Parkinson’s disease-second of two parts. N. Engl. J. Med. 339(16), 1130–1143 (1998).
   PubMed Web of Science ®Google Scholar
• Silver DE. Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®). Expert Rev. Neurotherapeutics 4(4), 589–599 (2004).
   PubMedGoogle Scholar
• Cedarbaum JM, Toy LH, Green-Parsons A. L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson’s disease patients with motor response fluctuations. Clin. Neuropharmacol. 14(3), 228–234 (1991).
   PubMed Web of Science ®Google Scholar
• Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM, and the Zydis Selegiline study group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov. Disord. 19(4), 426–432 (2004).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E et al. for the LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463), 947–954 (2005).
   PubMed Web of Science ®Google Scholar
• Mahmood I. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin. Pharmacokinet. 33(2), 91–102 (1997).
   PubMed Web of Science ®Google Scholar
• Shin HS. Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites. Drug Metab. Dispos. 25(6), 657–662 (1997).
   PubMed Web of Science ®Google Scholar
• Leopold NA, Kagel MC. Prepharyngeal dysphagia in Parkinson’s disease. Dysphagia 11(1), 14–22 (1996).
   PubMed Web of Science ®Google Scholar
• Fuh J-L, Lee R-C, Wang S-J et al. Swallowing difficulty in Parkinson’s disease. Clin. Neurol. Neurosurg. 99(2), 106–112 (1997).
   PubMed Web of Science ®Google Scholar
• Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry 63(2), 228–234 (1997).
   PubMed Web of Science ®Google Scholar
• Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson’s disease. Neurology 39(8), 1109–1111 (1989).
   PubMed Web of Science ®Google Scholar
• Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J. Pharm. Pharmacol. 50(4), 375–382 (1998).
   PubMed Web of Science ®Google Scholar
• Clarke A, Brewer F, Johnson ES et al. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition. J. Neural. Transm. 110(11), 1241–1255 (2003).
   PubMed Web of Science ®Google Scholar
• Clarke A, Johnson ES, Mallard N et al. A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition. J. Neural. Transm. 110(11), 1257–1271 (2003).
   PubMed Web of Science ®Google Scholar
• McCabe BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J. Am. Diet. Assoc. 86(8), 1059–1064 (1986).
   PubMed Web of Science ®Google Scholar
• Lasseter KC, Morganroth J, Shary W et al. Cardiac safety of a novel MAO-B inhibitor for the treatment of Parkinson’s disease. Presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders. New Orleans, LA, USA, March 5–8 (2005).
   Google Scholar
• Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline [letter]. Lancet 337(8735), 246 (1991); Comment in Lancet 337(8740), 554 (1991).
   PubMed Web of Science ®Google Scholar
• Heinonen EH, Myllyla V. Safety of selegiline (deprenyl) in the treatment of Parkinson’s disease. Drug Safety 19(1), 11–22 (1998).
   PubMed Web of Science ®Google Scholar